GlassScriptPhysician profile
Christen H Proffitt
NPI 1679765085
$4,996.75
in general payments reported to CMS, 2019-2025
43 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $1,394 · 2023: $1,354 · 2024: $859 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.96 | 2021-2024 | |
| Novo Nordisk INC | $584.07 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $505.94 | 2021-2024 | Mounjaro, Trulicity, Emgality |
| Amgen INC. | $475.68 | 2021-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $286.67 | 2021-2024 | Breztri, Airsupra |
| Pfizer INC. | $262.01 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.72 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $237.65 | 2021-2024 | Shingrix, Arexvy |
| Boston Scientific Corporation | $140.94 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $133.65 | 2022-2024 | Rexulti |
| Abbott Laboratories | $120.21 | 2022-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $111.63 | 2021-2023 | Ajovy |
| Biohaven Pharmaceuticals, INC. | $98.07 | 2021 | |
| Merck Sharp & Dohme LLC | $94.25 | 2021-2023 | Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.67 | 2021-2024 | Xifaxan, Relistor |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christen Proffitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.